Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1997;75(4):467–469. doi: 10.1038/bjc.1997.81

High-dose chemotherapy of metastatic breast cancer: the end of the beginning?

J Crown
PMCID: PMC2063305  PMID: 9052394

Full text

PDF
467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K., Ayash L., Elias A., Wheeler C., Hunt M., Eder J. P., Teicher B. A., Critchlow J., Bibbo J., Schnipper L. E. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan;10(1):102–110. doi: 10.1200/JCO.1992.10.1.102. [DOI] [PubMed] [Google Scholar]
  2. Ayash L. J., Elias A., Wheeler C., Reich E., Schwartz G., Mazanet R., Tepler I., Warren D., Lynch C., Gonin R. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol. 1994 Jan;12(1):37–44. doi: 10.1200/JCO.1994.12.1.37. [DOI] [PubMed] [Google Scholar]
  3. Bastholt L., Dalmark M., Gjedde S. B., Pfeiffer P., Pedersen D., Sandberg E., Kjaer M., Mouridsen H. T., Rose C., Nielsen O. S. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 1996 Apr;14(4):1146–1155. doi: 10.1200/JCO.1996.14.4.1146. [DOI] [PubMed] [Google Scholar]
  4. Bezwoda W. R., Seymour L., Dansey R. D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995 Oct;13(10):2483–2489. doi: 10.1200/JCO.1995.13.10.2483. [DOI] [PubMed] [Google Scholar]
  5. Brugger W., Birken R., Bertz H., Hecht T., Pressler K., Frisch J., Schulz G., Mertelsmann R., Kanz L. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol. 1993 Jul;84(3):402–407. doi: 10.1111/j.1365-2141.1993.tb03093.x. [DOI] [PubMed] [Google Scholar]
  6. Brugger W., Heimfeld S., Berenson R. J., Mertelsmann R., Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med. 1995 Aug 3;333(5):283–287. doi: 10.1056/NEJM199508033330503. [DOI] [PubMed] [Google Scholar]
  7. Castella J., Buj J., Puzo C., Antón P. A., Burgués C. Diagnosis and staging of bronchogenic carcinoma by transtracheal and transbronchial needle aspiration. Ann Oncol. 1995;6 (Suppl 3):S21–S24. doi: 10.1093/annonc/6.suppl_3.s21. [DOI] [PubMed] [Google Scholar]
  8. Cold S., Jensen N. V., Brincker H., Rose C. The influence of chemotherapy on survival after recurrence in breast cancer--a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer. 1993;29A(8):1146–1152. doi: 10.1016/s0959-8049(05)80305-3. [DOI] [PubMed] [Google Scholar]
  9. Crown J., Hamilton N., Raptis G., Kritz A., Vahdat L., Norton L. Carboplatin and etoposide in metastatic breast cancer. Ann Oncol. 1995 Apr;6(4):403–403. doi: 10.1093/oxfordjournals.annonc.a059191. [DOI] [PubMed] [Google Scholar]
  10. Crown J., Kritz A., Vahdat L., Reich L., Moore M., Hamilton N., Schneider J., Harrison M., Gilewski T., Hudis C. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1993 Jun;11(6):1144–1149. doi: 10.1200/JCO.1993.11.6.1144. [DOI] [PubMed] [Google Scholar]
  11. Crown J., Wassherheit C., Hakes T., Fennelly D., Reich L., Moore M., Schneider J., Curtin J., Rubin S. C., Reichman B. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J Natl Cancer Inst. 1992 Dec 16;84(24):1935–1936. doi: 10.1093/jnci/84.24.1935. [DOI] [PubMed] [Google Scholar]
  12. Decker D. A., Ahmann D. L., Bisel H. F., Edmonson J. H., Hahn R. G., O'Fallon J. R. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA. 1979 Nov 9;242(19):2075–2079. [PubMed] [Google Scholar]
  13. Devita V. T., Jr, Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881–895. doi: 10.7326/0003-4819-73-6-881. [DOI] [PubMed] [Google Scholar]
  14. Dunphy F. R., Spitzer G. Use of very-high-dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst. 1992 Jan 15;84(2):128–129. doi: 10.1093/jnci/84.2.128. [DOI] [PubMed] [Google Scholar]
  15. Eder J. P., Antman K., Peters W., Henner W. D., Elias A., Shea T., Schryber S., Andersen J., Come S., Schnipper L. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov;4(11):1592–1597. doi: 10.1200/JCO.1986.4.11.1592. [DOI] [PubMed] [Google Scholar]
  16. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  17. Fennelly D., Schneider J., Spriggs D., Bengala C., Hakes T., Reich L., Barakat R., Curtin J., Moore M. A., Hoskins W. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol. 1995 May;13(5):1160–1166. doi: 10.1200/JCO.1995.13.5.1160. [DOI] [PubMed] [Google Scholar]
  18. Forastiere A. A., Hakes T. B., Wittes J. T., Wittes R. E. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol. 1982 Jun;5(3):243–247. doi: 10.1097/00000421-198206000-00001. [DOI] [PubMed] [Google Scholar]
  19. Ghalie R., Richman C. M., Adler S. S., Cobleigh M. A., Korenblit A. D., Manson S. D., McLeod B. C., Taylor S. G., 4th, Valentino L. A., Wolter J. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb;12(2):342–346. doi: 10.1200/JCO.1994.12.2.342. [DOI] [PubMed] [Google Scholar]
  20. Gianni A. M., Siena S., Bregni M., Tarella C., Stern A. C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989 Sep 9;2(8663):580–585. doi: 10.1016/s0140-6736(89)90711-3. [DOI] [PubMed] [Google Scholar]
  21. Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
  22. Henderson I. C. Window of opportunity. J Natl Cancer Inst. 1991 Jul 3;83(13):894–896. doi: 10.1093/jnci/83.13.894. [DOI] [PubMed] [Google Scholar]
  23. Hortobagyi G. N., Bodey G. P., Buzdar A. U., Frye D., Legha S. S., Malik R., Smith T. L., Blumenschein G. R., Yap H. Y., Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar;5(3):354–364. doi: 10.1200/JCO.1987.5.3.354. [DOI] [PubMed] [Google Scholar]
  24. Kennedy M. J., Beveridge R. A., Rowley S. D., Gordon G. B., Abeloff M. D., Davidson N. E. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991 Jul 3;83(13):920–926. doi: 10.1093/jnci/83.13.920. [DOI] [PubMed] [Google Scholar]
  25. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986 Jan;70(1):163–169. [PubMed] [Google Scholar]
  26. Patrone F., Ballestrero A., Ferrando F., Brema F., Moraglio L., Valbonesi M., Basta P., Ghio R., Gobbi M., Sessarego M. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol. 1995 Apr;13(4):840–846. doi: 10.1200/JCO.1995.13.4.840. [DOI] [PubMed] [Google Scholar]
  27. Perloff M., Norton L., Korzun A. H., Wood W. C., Carey R. W., Gottlieb A., Aust J. C., Bank A., Silver R. T., Saleh F. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May;14(5):1589–1598. doi: 10.1200/JCO.1996.14.5.1589. [DOI] [PubMed] [Google Scholar]
  28. Peters W. P., Rosner G., Ross M., Vredenburgh J., Meisenberg B., Gilbert C., Kurtzberg J. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood. 1993 Apr 1;81(7):1709–1719. [PubMed] [Google Scholar]
  29. Peters W. P., Ross M., Vredenburgh J. J., Meisenberg B., Marks L. B., Winer E., Kurtzberg J., Bast R. C., Jr, Jones R., Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun;11(6):1132–1143. doi: 10.1200/JCO.1993.11.6.1132. [DOI] [PubMed] [Google Scholar]
  30. Peters W. P., Shpall E. J., Jones R. B., Olsen G. A., Bast R. C., Gockerman J. P., Moore J. O. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1368–1376. doi: 10.1200/JCO.1988.6.9.1368. [DOI] [PubMed] [Google Scholar]
  31. Rodenhuis S., Westermann A., Holtkamp M. J., Nooijen W. J., Baars J. W., van der Wall E., Slaper-Cortenbach I. C., Schornagel J. H. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol. 1996 May;14(5):1473–1483. doi: 10.1200/JCO.1996.14.5.1473. [DOI] [PubMed] [Google Scholar]
  32. Shpall E. J., Jones R. B., Bearman S. I., Franklin W. A., Archer P. G., Curiel T., Bitter M., Claman H. N., Stemmer S. M., Purdy M. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol. 1994 Jan;12(1):28–36. doi: 10.1200/JCO.1994.12.1.28. [DOI] [PubMed] [Google Scholar]
  33. Vahdat L., Raptis G., Fennelly D., Hamilton N., Reich L., Tiersten A., Harrison M., Hudis C., Moore M., Yao T. J. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res. 1995 Nov;1(11):1267–1273. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES